<abstract xmlns="http://www.w3.org/1999/xhtml"><p>In the last few years, obesity has become a global epidemic. Consequently, worldwide costs associated with managing obesity and obesity-related comorbidities are huge. Numerous studies have focused on discerning the appropriate proper treatment of weight related problems such as overweight and obesity. Moreover, many clinical trials have been conducted for many years in order to introduce effective anti-obesity drugs. The aim of the present review is to provide an overview of current and future pharmacotherapy for obesity, and to provide the reader with a determination of the concentration and composition of long and short term anti-obesity drugs, doing so by placing emphasis on pharmacotherapy and up-to-day solutions. It should be noted that, currently, the worldwide pharmacotherapy is represented by phendimetrazine, benzphetamine and diethylpropion, as well as by orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide. In our paper, individual cases of patients’ needs are thoroughly illustrated by way of examples. Medical prescriptions and contraindications are also described.</p></abstract>

In the last few years, obesity has become a global epidemic. Consequently, worldwide costs associated with managing obesity and obesity-related comorbidities are huge. Numerous studies have focused on discerning the appropriate proper treatment of weight related problems such as overweight and obesity. Moreover, many clinical trials have been conducted for many years in order to introduce effective anti-obesity drugs. The aim of the present review is to provide an overview of current and future pharmacotherapy for obesity, and to provide the reader with a determination of the concentration and composition of long and short term anti-obesity drugs, doing so by placing emphasis on pharmacotherapy and up-to-day solutions. It should be noted that, currently, the worldwide pharmacotherapy is represented by phendimetrazine, benzphetamine and diethylpropion, as well as by orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide. In our paper, individual cases of patients’ needs are thoroughly illustrated by way of examples. Medical prescriptions and contraindications are also described.

Contemporary pharmacological obesity treatments

Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki, 20-093 Lublin, Poland

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Contemporary pharmacological obesity treatments"}

In the last few years, obesity has become a global epidemic. Consequently, worldwide costs associated with managing obesity and obesity-related comorbidities...

Contemporary pharmacological obesity treatments

Publié en ligne: 08 juin 2016

Pages: 57 - 60

Reçu: 08 févr. 2016

Accepté: 14 mars 2016

DOI: https://doi.org/10.1515/cipms-2016-0012

Mots clés
pharmacotherapy, obesity, Body Mass Index, drug

© 2016 Katarzyna Kaszubska et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Contemporary pharmacological obesity treatments

Publié en ligne: 08 juin 2016

Pages: 57 - 60

Reçu: 08 févr. 2016

Accepté: 14 mars 2016

DOI: https://doi.org/10.1515/cipms-2016-0012

Mots cléspharmacotherapy, obesity, Body Mass Index, drug

© 2016 Katarzyna Kaszubska et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
pharmacotherapy, obesity, Body Mass Index, drug